Sector
PharmaceuticalsOpen
₹23.99Prev. Close
₹23.11Turnover(Lac.)
₹0Day's High
₹23.99Day's Low
₹23.9952 Week's High
₹3952 Week's Low
₹19.99Book Value
₹7Face Value
₹10Mkt Cap (₹ Cr.)
10.75P/E
25.4EPS
0.91Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 4.48 | 4.48 | 4.48 | 4.48 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -1.75 | -2.03 | -2.31 | -2.56 |
Net Worth | 2.73 | 2.45 | 2.17 | 1.92 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 9.95 | 10.6 | 11.29 | 12.24 |
yoy growth (%) | -6.09 | -6.13 | -7.72 | 18.08 |
Raw materials | -7.55 | -8.2 | -9.44 | -10.37 |
As % of sales | 75.88 | 77.36 | 83.64 | 84.72 |
Employee costs | -0.47 | -0.44 | -0.44 | -0.39 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 0.1 | 0.3 | 0.26 | 0.29 |
Depreciation | -0.08 | -0.07 | -0.1 | -0.08 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.12 | 0.86 | 0.28 | 0.14 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -6.09 | -6.13 | -7.72 | 18.08 |
Op profit growth | -44.02 | -27.63 | -9.26 | 3.42 |
EBIT growth | -35.35 | 52.71 | -29.8 | 10.44 |
Net profit growth | -66.42 | 17.43 | -11.15 | 14.86 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Krutiben M Patel
Independent Director
Hasmukh S Darji
Chairman (Non-Executive)
Jashodaben S Patel
Independent Director
Jitendrakumar Parshottamdas Limbachiya
Company Sec. & Compli. Officer
Jigar Ray
Independent Director
Mustufa Najmuddin
Executive Director
Esham. Patel
Khali Char Rasta,
State Highway Ta Sidhpur,
Gujarat - 384151
Tel: 91-2767-282395
Website: http://www.unjhaformulations.com
Email: info@unjhaformulations.com ; unjfor@bsnl.in
5th Floor 506 to 508,
ABC-I Off C G Road, Navrangpura,
Ahmedabad-380009
Tel: 91-79-26465179
Website: https://in.mpms.mufg.com/
Email: ipo.team@linkintime.co.in
Summary
Unjha Formulations Ltd was established in Jun.87 as a partnership firm for manufacturing pharmaceutical formulations in the Mehsana district of Gujarat. It was promoted by Shambhubhai A Patel. The Com...
Read More
Reports by Unjha Formulations Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.